9 Meters Biopharma Inc. (NMTRQ)
OTCMKTS: NMTRQ · Delayed Price · USD
0.00
0.00 (0.00%)
Apr 30, 2024, 3:05 PM EDT - Market open

9 Meters Biopharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current202220212020201920182017201620152014
Market Capitalization
0162501292060613--
Market Cap Growth
--93.48%93.78%545.94%-66.81%948.00%-55.26%---
Enterprise Value
-36203911960141145
PE Ratio
-0.43-0.37-6.80-2.10-0.74-2.49-0.49-2.07--
PS Ratio
-------3.16--
PB Ratio
-3.166.806.014.02-2.08-16.46-0.475.16--
P/FCF Ratio
-0.54-0.44-8.48-6.65-1.11-3.97-1.12-1.52--
P/OCF Ratio
-0.54-0.44-8.49-6.65-1.11-3.97-1.13-1.52--
EV/Sales Ratio
-------2.810.440.44
EV/EBITDA Ratio
-0.41-0.15-5.54-1.59-0.73-3.31-1.25-2.12-0.49-0.53
EV/EBIT Ratio
-0.41-0.15-5.54-1.59-0.73-3.31-1.25-2.12-0.49-0.53
EV/FCF Ratio
-0.47-0.17-6.90-4.71-1.03-3.93-2.72-1.36-2.08-0.67
Debt / Equity Ratio
-0.818.190.000.01-0.33-1.42-0.700.02-0.65-1.02
Debt / EBITDA Ratio
-0.12-0.480.000.00-0.13-0.29-0.77-0.01-0.51-0.54
Debt / FCF Ratio
-0.14-0.530.00-0.01-0.18-0.34-1.670.00-2.15-0.68
Quick Ratio
0.490.975.565.540.310.570.030.580.070.32
Current Ratio
0.591.085.915.680.350.630.061.010.150.56
Asset Turnover
00000000.731.49-
Interest Coverage
-12.53-15.41-778.42-14.20-13.82-2.93-25.60-6.53-5.33-5.65
Return on Equity (ROE)
-585.00%-254.10%-79.90%-936.00%1716.00%-1204.00%360.20%387.60%163.70%-
Return on Assets (ROA)
-159.50%-119.90%-69.10%-346.30%-255.60%-245.40%-381.70%-111.10%-157.10%-
Return on Capital (ROIC)
3640.38%-190.40%-88.12%-166.19%377.69%-1185.23%310.20%-235.27%327.25%-6812.24%
Earnings Yield
-3200769.92%-268.11%-14.70%-47.62%-135.31%-40.12%-201.96%-48.38%--
FCF Yield
-2575695.85%-228.17%-11.79%-15.03%-89.94%-25.21%-89.36%-65.61%--
Buyback Yield / Dilution
-5.27%-6.58%-130.12%-216.97%-34.59%-108.29%-2053.67%-67.58%-17.62%-
Total Shareholder Return
-5.27%-6.58%-130.12%-216.97%-34.59%-108.29%-2053.67%-67.58%-17.62%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).